The ASH Research Collaborative’s (ASH RC’s) Data Hub recently launched a new COVID-19 Registry for Hematology, a global registry with clinical data on people with COVID-19 and a current or past diagnosis of a hematologic disease. Originally launched on April 1 with a focus on malignant hematology, the registry will soon be expanded to begin accepting data on patients with preexisting nonmalignant hematologic disorders, as well as those who develop hematologic complications associated with COVID-19.
Clinicians and other health-care providers worldwide are strongly encouraged to enter de-identified data on all confirmed COVID-19 cases for patients with hematologic conditions, regardless of recovery or active treatment status; entry can be completed in less than 5 minutes. Data will be analyzed and summarized in the aggregate to provide near real-time observational data summaries to clinicians on the front lines of the COVID-19 pandemic. The Registry was determined to be exempt under 45 CFR § 46.104(d)(4) and approved for a waiver of authorization by the Western Institutional Review Board.
“We initially developed the malignant hematology COVID registry after hearing from frontline hematologists that data were needed to help understand the impact of COVID on patients with blood cancers, said William A. Wood Jr., MD, MPH, Associate Professor of Medicine at the University of North Carolina School of Medicine and Chair of the ASH RC’s Data Hub Oversight Group. “With our initial data, we’re already starting to address that need, but we’re also recognizing that similar data are needed for patients with underlying nonmalignant conditions and hematologic complications of COVID such as coagulopathy and thrombosis. We hope that our registry will provide useful insights to hematologists worldwide while generating additional hypotheses for follow-on focused research efforts.”
The Registry is a new addition to the ASH RC Data Hub that launched in 2018 as a platform designed to accelerate scientific discovery by gathering and facilitating the sharing of clinical data on rare blood diseases. In addition to the surveillance data related to COVID-19, the Data Hub also houses data on more than 3,000 patients with sickle cell disease and more than 2,000 patients with multiple myeloma.
Learn more or submit a case here.
Now Open: Honorific Award Nominations
Each year, ASH honors outstanding hematologists with the ASH Honorific Awards, the Society’s most prestigious awards, recognizing hematologists’ significant contributions to the field.
For information about each award and the nomination process and to nominate someone by July 15, visit our website.
2019 ASH Annual Report Now Available!
As we work together to address the current challenges brought about by the coronavirus pandemic, we also want to reflect on the many successes ASH enjoyed in 2019 – and to thank everyone who made them possible.
Learn about the achievements of ASH’s powerful community of members, volunteers, and staff through the Society’s 2019 Annual Report here.
COVID-19 Podcast Series from The Hematologist
ASH’s official member newsletter, The Hematologist, has launched a podcast series providing weekly updates on ASH resources for the hematology community regarding the COVID-19 public health crisis. The series provides as a space for members and other health care professionals to share their experiences on the front lines and provide support for their colleagues.
The Hematologist Editor-in-Chief Laura Michaelis, MD, hosts conversations with health care professionals about topics ranging from the use of social media to disseminate information during a public health crisis to supporting health-care professionals who are caring for patients with COVID-19. The series will also include updates on blood transfusions, the blood supply shortage, and the use of convalescent plasma to fight the pandemic.
Subscribe on Apple Podcasts or find the full playlist on Soundcloud.
Become an ASH Choosing Wisely Champion!
The ASH Choosing Wisely Champions initiative, presented with the American Board of Internal Medicine (ABIM) Foundation, was created to recognize the efforts of practitioners who have successfully implemented projects to eliminate costly and potentially harmful overuse of tests and procedures in their practice, institution, or hospital system. Each year, three nominees are selected to present their projects at the ASH annual meeting, providing attendees with an opportunity to learn about successful strategies that might be translated to their own practices.
Submissions from previous applicants are encouraged, as are projects from across the full spectrum of hematology, including adult and pediatric, malignant and nonmalignant, transfusion, and lab-based hematology.
Clinicians, researchers, and trainees at all levels in both academic and community settings should apply by June 1 here.